MariMed reports FY2025 revenue of $159.8M, net loss widens to $14.5M, adjusted EBITDA down to $16.9M

MARIMED INC.

FY2025 revenue $159.8M, up from $157.7M in FY2024; Q4 revenue $41.7M vs $38.9M.
GAAP net loss $14.5M in FY2025 vs $12.4M; Non-GAAP adjusted EBITDA $16.9M, down from $19.3M.
Wholesale revenue increased 11%; distribution reached 85% of dispensaries in core markets.
Betty's Eddies ranked #1 edible in MA, MD, DE, IL; restructured Series B debt, extending maturity 4.6 years.
CEO cites growth drivers for 2026: Delaware adult-use, Maine brand licensing, new Columbus OH dispensary.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.